$87.7 Million is the total value of Asymmetry Capital Management, L.P.'s 38 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 118.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OPTN | Buy | OPTINOSE INC | $6,785,000 | +19.4% | 338,925 | +12.7% | 8.49% | +10.0% |
| CNC | Buy | CENTENE CORP | $5,159,000 | +11.1% | 48,276 | +4.9% | 6.45% | +2.4% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $3,780,000 | +56.8% | 69,676 | +72.8% | 4.73% | +44.5% |
| INSM | Buy | INSMED INC | $3,652,000 | -26.0% | 162,185 | +2.5% | 4.57% | -31.8% |
| NTRA | Buy | NATERA INC | $3,018,000 | +68.0% | 325,529 | +62.9% | 3.78% | +54.8% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $2,473,000 | +28.5% | 29,825 | +20.3% | 3.09% | +18.5% |
| KALA | Buy | KALA PHARMACEUTICALS | $2,125,000 | +750.0% | 134,250 | +894.1% | 2.66% | +684.1% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $1,935,000 | +259.0% | 135,974 | +121.0% | 2.42% | +230.6% |
| PFE | New | PFIZER INC | $1,890,000 | – | 53,242 | +100.0% | 2.36% | – |
| BSX | New | BOSTON SCIENTIFIC CORP | $1,865,000 | – | 68,270 | +100.0% | 2.33% | – |
| LJPC | New | LA JOLLA PHARMACEUTICAL CO | $1,664,000 | – | 55,864 | +100.0% | 2.08% | – |
| INGN | New | INOGEN INC | $1,532,000 | – | 12,471 | +100.0% | 1.92% | – |
| ARRY | Buy | ARRAY BIOPHARMA INC | $1,333,000 | +57.6% | 81,649 | +23.5% | 1.67% | +45.2% |
| PBYI | Buy | PUMA BIOTECHNOLOGYINC | $1,229,000 | +68.6% | 18,057 | +145.0% | 1.54% | +55.4% |
| PEN | New | PENUMBRA INC | $1,189,000 | – | 10,279 | +100.0% | 1.49% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INC | $1,063,000 | – | 22,000 | +100.0% | 1.33% | – |
| EXAS | New | EXACT SCIENCES CORP | $1,041,000 | – | 25,803 | +100.0% | 1.30% | – |
| TVTY | New | TIVITY HEALTH INC | $975,000 | – | 24,601 | +100.0% | 1.22% | – |
| KDMN | New | KADMON HOLDINGS INC | $846,000 | – | 199,147 | +100.0% | 1.06% | – |
| ECYT | Buy | ENDOCYTE | $831,000 | +138.1% | 91,435 | +12.2% | 1.04% | +119.2% |
| NCNA | New | NUCANA PLCadr | $765,000 | – | 40,448 | +100.0% | 0.96% | – |
| RGNX | New | REGENXBIO INC | $478,000 | – | 16,008 | +100.0% | 0.60% | – |
| OPK | New | OPKO HEALTH INC | $447,000 | – | 141,044 | +100.0% | 0.56% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $14,000 | – | 1,700 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.